MedTrace Logo

AV133 Longitudinal Imaging Study in Patients With Early and Prdromal Parkinson's Disease

NCT06456684 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2024-06-13

No results posted yet for this study

Summary

A total of 38 patients with early-stage Parkinson's disease and 38 patients with prodromal Parkinson's disease are planned to be enrolled in this study and examined for longitudinal changes in \[18F\]AV-133 through follow-up, thereby informing the design of future therapeutic trials utilizing \[18F\]AV-133 as a marker of disease progression.

Conditions

  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

Fluoro[18F]promethazine

It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease

Sponsors & Collaborators

  • The Michael J. Fox Foundation for Parkinson's Research

    collaborator UNKNOWN

  • XINGIMAGING LLC

    collaborator UNKNOWN

  • Naming MITRO Pharmaceutical Technology Co., Ltd

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06456684 on ClinicalTrials.gov